The research compound in Mounjaro^®

Mounjaro^® is a type 2 diabetes medicine from Eli Lilly and Company. Its active compound is Tirzepatide — which is what this catalogue supplies, as a research material.

This is not Mounjaro^®, and NOVALYTE LABS has no affiliation with Eli Lilly and Company. We supply the compound Tirzepatide for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Mounjaro^® is a trademark of Eli Lilly and Company, referenced here only to identify the compound.

Mounjaro is the brand under which Eli Lilly markets tirzepatide for type 2 diabetes. The same molecule is marketed as Zepbound for weight management — one compound, two brands, two indications.

Tirzepatide itself is a dual agonist: a single 39-amino-acid peptide engineered to activate both the GIP and GLP-1 receptors, which is what distinguishes it from the single-receptor GLP-1 agonists that preceded it.

What this catalogue supplies is tirzepatide as a research material, with batch documentation. It is not Mounjaro, it is not a medicine, and it is not supplied for human use.

Tirzepatide in this catalogue

Other brands using Tirzepatide

The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.